These data are consistent with the observed role of β-arrestin1 in impeding p62/SQSTM1 flux and impairing destruction of misfolded tau (83) and underline the potential of β-arrestin proteins as drug targets for the therapy of neurodegenerative diseases. Here, MAPT is linked to neurodegenerative disease.